Biomarkers Predicting New-Onset Atrial Fibrillation: Systematic Review & Meta-Analysis

Overview

This systematic review and meta-analysis of 10 cohort studies including 472,581 patients identified 18 biomarkers associated with increased risk of new-onset atrial fibrillation (AF), notably NT-proBNP and sVCAM-1. Elevated NT-proBNP was significantly linked to higher AF incidence (HR 1.37), while some biomarkers like ADAMTS13 were associated with reduced AF risk.

Background

Atrial fibrillation is the most common arrhythmia globally, increasing risks of stroke, heart failure, and mortality. Early diagnosis is challenging due to asymptomatic or silent AF, often delaying treatment. Biomarkers reflecting myocardial stress, inflammation, and endothelial dysfunction have emerged as potential tools for early AF detection and risk stratification. Identifying reliable biomarkers could improve preventive management and reduce adverse cardiovascular events.

Data Highlights

Key Findings

• 18 biomarkers were associated with increased incidence of new-onset AF, with NT-proBNP and sVCAM-1 being the most notable.
• Elevated NT-proBNP levels showed a significant association with higher AF risk (HR 1.37, 95% CI 1.19–1.59), despite high heterogeneity among studies.
• Lipoprotein(a) levels were linked to a modest but significant increase in AF incidence (3% increase per 20 mg/dL increment).
• Nine biomarkers, including ADAMTS13, were associated with a lower incidence of AF, suggesting potential protective roles.
• Biomarkers reflect diverse pathophysiological pathways such as myocardial stress, inflammation, and endothelial dysfunction relevant to AF development.
• Networks constructed from biomarker associations highlight complex interactions that may inform future diagnostic and preventive strategies.

Clinical Implications

Measurement of NT-proBNP and emerging biomarkers like sVCAM-1 and Lp(a) may enhance early identification of patients at risk for new-onset AF, enabling timely intervention. Incorporating these biomarkers into clinical practice could improve risk stratification and guide preventive management to reduce stroke and cardiovascular complications. However, large prospective studies are needed to validate their diagnostic utility and optimize clinical application.

Conclusion

This comprehensive review confirms that established and novel biomarkers are significantly associated with new-onset AF risk, underscoring their potential role in early diagnosis and prevention. Future research should focus on validating these findings to integrate biomarker assessment into routine AF risk management.

References

1. Biomarker Discovery for Anticipating New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis